Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer

This prospective, single-center, randomized controlled trial aims to assessing the efficacy and safety of neoadjuvant chemoradiation plus Tislelizumab (PD-1 inhibitor) with or without Probio-M9 and subsequent TME surgery, by comparing assorted endpoints between two experiment groups (Experiment group 1: chemoradiation+PD-1 inhibitor+Probio-M9; Experiment group 2: chemoradiation+PD-1 inhibitor+placebo) with a control group (chemoradiation only).

Trial Details

NCT ID
NCT07458529
Phase
PHASE2
Sponsor
Seventh Medical Center of PLA General Hospital
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • CRT+PD-1 inhibitor+Probio-M9
  • CRT+PD-1 inhibitor+placebo
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Age ≥ 18 years
  • ECOG performance status 0-2
  • Biopsy-proven rectal adenocarcinoma
  • Distal tumor margin within 10 cm of the anal verge

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →